MarketVIEW - Chagas disease vaccines -, GA News Weather & Sports

MarketVIEW - Chagas disease vaccines

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE ReportBuyer




LONDON, July 7, 2014 /PRNewswire/ -- has added a new market research report:

MarketVIEW - Chagas disease vaccines

Chagas disease, is caused by the protozoan parasite Trypanasoma cruzi (T.cruzi). T.cruzi mainly infects young children living in poverty and it is estimated that around 10 million people carry the pathogen with 99% living in Latin America. After acute infection most individuals remain in an asymptomatic indeterminate disease phase, which can last for decades. However, around 30 to 40% progress to chronic disease (determinate phase) , which includes serious cardiac and gastrointestinal manifestations. It is estimated that around 10,000 deaths occur each year due to chronic Chagas disease with substantial economic losses.

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for T.cruzi vaccine profiles in the LATAM, US and EU regions. Two therapeutic vaccine profiles (TX) are modelled in determinate and indeterminate populations to 2034 , along with investigation also of a prophylactic (PX) vaccine profile. The analysis provides an up-to-date review of the literature in terms of epidemiology, treatment, cost implications coupled with a review of vaccine development history to date. Clear assumptions are provided in terms of prospective vaccine launch date, penetration estimates, pricing estimates and gross revenue forecasts.

Contents – Summary presentation (MS PowerPoint based)

Author's note
Executive Summary
T.cruzi therapeutic vaccine: potential revenues to 2034 per scenario
T.cruzi therapeutic vaccine: potential volumes to 2034 per scenario
T.cruzi therapeutic vaccine: potential revenues to 2034 per region LO
T.cruzi therapeutic vaccine: potential revenues to 2034 per region HI
T.cruzi prophylatic vaccine: potential revenues to 2034 per scenario
T.cruzi prophylatic vaccine: potential volumes to 2034 per scenario
T.cruzi therapeutic vaccine: sensitivity analysis
Chagas disease: Disease background and epidemiology
Chagas disease: introduction
Trypanosoma cruzi: geographical distribution
Trypanosoma cruzi: distribution of cases of infection 2006-2009
Chagas disease: prevalence (major countries)
Trypanosoma cruzi: endemic zones
Chagas disease: infected individuals, DALYS
Chagas disease: overall morbidity & mortality
The parasite: Trypanosoma cruzi
Natural history of Chagas disease
Trypanosoma cruzi: life-cycle
Trypanosoma cruzi: vectors
Trypanosoma cruzi: major triatomine species
Trypanosoma cruzi: hosts
Trypanosoma cruzi: variables influencing human infection
Trypanosoma cruzi: other modes of transmission
Trypanosoma cruzi: summary of transmission routes
Chagas disease: country groupings and disease characteristics
Trypanosoma cruzi: vector control
Trypanosoma cruzi: impact of immigration
Trypanosoma cruzi: United States
Trypanosoma cruzi: immigrants to selected EU countries1
Chagas disease: clinical aspects
Chagas disease: diagnosis
Chagas disease: flowchart
Chagas disease: clinical aspects - acute phase
Chagas disease: clinical aspects - interdeterminate/chronic phase
Chagas disease: cardiac form
Chagas heart disease
Chagas disease: digestive form
Chagas disease: clinical forms and age groups
Chagas disease: current treatment
Chagas disease treatments: cost of therapy
Chagas disease: vaccine development
Trypanosoma cruzi: immune response
Trypanosoma cruzi: an autoimmune phenomena?
Trypanosoma cruzi: rationale for vaccine development
Trypanosoma cruzi: stages for vaccine development
Desirable immune responses of a Trypanosoma cruzi vaccine
Trypanosoma cruzi: vaccine development history
Trypanosoma cruzi vaccines: preclinical subunit approaches
Trypanosoma cruzi: DNA vaccine approaches
Trypanosoma cruzi: therapeutic vaccination background
Performance of TSA-1 and Tc24 antigens
T. cruzi therapeutic vaccine initiative: Sabin PDP
T. cruzi therapeutic vaccine initiative: partners
T. cruzi therapeutic vaccine initiative: activities
T. cruzi therapeutic vaccine initiative: roles/responsibilities
Trypanosoma cruzi vaccine(s): developmental challenges
Trypanosoma cruzi vaccines: TcVAC-3
Chagas disease: overall research priorities
Chagas disease: research into new treatments
T.cruzi therapeutic vaccine: modelling commercial potential
T.cruzi therapeutic vaccine: modelling strategy
T.cruzi therapeutic vaccine: target product profile (TPP) – LO
T.cruzi therapeutic vaccine: target product profile (TPP) – HI
T.cruzi therapeutic vaccine: modelling scenarios
TX Modelling strategy: populations/target groups/presentation
TX Modelling strategy: product penetration/introduction
T.cruzi therapeutic vaccine: penetration rates chosen
T.cruzi therapeutic vaccine: compliance/boosting rates chosen
Trypanosoma cruzi vaccines: cost effectiveness
T.cruzi therapeutic vaccine: pricing estimates used in model
T.cruzi prophylatic vaccine: modelling commercial potential
T.cruzi prophylatic vaccine: target product profile (TPP)
T.Cruzi prophylactic vaccine: modelling strategy
About VacZine Analytics

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Prophylactic vaccine
PX charts – VOL VAL
Therapeutic vaccine
TX charts – VOL
TX charts – VAL
Grand scenario summary – TX
Val sum Hi scenario
Val sum Lo scenario
Global price summary
Vol sum Hi scenario
Vol sum Lo scenario
Country worksheets
Canada low
Canada hi,
Mexico low
Mexico hi,
El Salvador low
El Salvador hi,
Honduras low
Honduras hi
Guatemala low
Guatemala low
Nicaragua low
Nicaragua hi
Argentina lo
Argentina hi,
Bolivia low
Bolivia hi,
Brazil low
Brazil hi,
Chile low
Chile hi,
Colombia low
Colombia high
Ecuador low
Ecuador hi,
Paraguay low
Paraguay hi,
Peru low
Peru hi,
Venezuela low
Venezuela hi,
Other LATAM low
Other LATAM hi,
EU low
EU high
Source material
T. Cruzi prevalence
EU immigration
Population >2 yrs
Population >14 yrs


Read the full report:
MarketVIEW - Chagas disease vaccines

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

1909 Wynnton Road
Columbus, Ga. 31906

FCC Public File
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WTVM. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.